Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
0.00% $0.750
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2.09 mill |
EPS: | -2.12 |
P/E: | -0.350 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 2.78 mill |
Avg Daily Volume: | 0.0690 mill |
RATING 2024-04-25 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.350 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.350 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.674 - 0.826 ( +/- 10.13%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-23 | Mika Thomas | Buy | 16 666 | Option to Purchase Common Stock |
2024-01-23 | Jacob Harold | Buy | 6 667 | Option to Purchase Common Stock |
2024-01-23 | Schroeder Maria | Buy | 16 667 | Option to Purchase Common Stock |
2024-01-23 | Ferguson Michael | Buy | 16 666 | Option to Purchase Common Stock |
2024-01-23 | Goldstein Martin M | Buy | 16 667 | Option to Purchase Common Stock |
INSIDER POWER |
---|
29.25 |
Last 97 transactions |
Buy: 2 103 083 | Sell: 846 526 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $0.750 (0.00% ) |
Volume | 0.0081 mill |
Avg. Vol. | 0.0690 mill |
% of Avg. Vol | 11.77 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.